Femasys Inc. Begins FemBloc Pivotal Trial Enrollment at UC Davis Medical Center, a Hub for Innovation and Groundbreaking Research in Health Care for Women
Femasys Inc. (FEMY)
Company Research
Source: GlobeNewswire
UC Davis Medical Center, a top regional and nationally ranked medical center, is the third academic center to participate in the FemBloc pivotal trial since enrollment began last quarter -UC Davis Professor of the Obstetrics and Gynecology (OB/GYN) Department and Director of the Complex Family Planning Fellowship, Mitchell Creinin, M.D. has been an initial advisor for FemBloc -FemBloc is being developed as a first-of-its-kind, non-surgical, permanent birth control with a clearly defined U.S. regulatory pathway - ATLANTA, Jan. 26, 2024 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ: FEMY), a biomedical company focused on meeting significant unmet needs for women worldwide with a broad portfolio of in-office, accessible solutions, including a lead, late-clinical stage product candidate and innovative therapeutic and diagnostic products, today announced that it has activated enrollment for its pivotal FemBloc® trial at University of California, Davis (“UC Davis”) Medical Center in Sac
Show less
Read more
Impact Snapshot
Event Time:
FEMY
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
FEMY alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
FEMY alerts
High impacting Femasys Inc. news events
Weekly update
A roundup of the hottest topics
FEMY
News
- Femasys CEO and Founder Kathy Lee-Sepsick Meets with Members of Congress to Raise Awareness of the Company and Discuss Women's Healthcare Initiatives [Yahoo! Finance]Yahoo! Finance
- Femasys CEO and Founder Kathy Lee-Sepsick Meets with Members of Congress to Raise Awareness of the Company and Discuss Women’s Healthcare InitiativesGlobeNewswire
- Femasys Inc. (NASDAQ: FEMY) had its "buy" rating re-affirmed by analysts at Chardan Capital. They now have a $12.00 price target on the stock.MarketBeat
- Femasys Inc. (NASDAQ: FEMY) had its price target raised by analysts at HC Wainwright from $10.00 to $12.00. They now have a "buy" rating on the stock.MarketBeat
- Femasys Full Year 2023 Earnings: EPS Beats Expectations, Revenues Lag [Yahoo! Finance]Yahoo! Finance
FEMY
Sec Filings
- 4/26/24 - Form 10-K/A
- 4/24/24 - Form 8-K
- 4/5/24 - Form S-8
- FEMY's page on the SEC website